Travere Therapeutics, Inc. Common Stock Earnings Dividend
Earnings Summary
Revenue | $169.58Mn |
Net Profits | $-34.8Mn |
Net Profit Margins | -20.52% |
Travere Therapeutics, Inc. Common Stock’s revenue jumped 48.17% since last year same period to $169.58Mn in the Q2 2026. On a quarterly growth basis, Travere Therapeutics, Inc. Common Stock has generated 33.32% jump in its revenue since last 3-months.
Travere Therapeutics, Inc. Common Stock’s net profit fell -172.81% since last year same period to $-34.8Mn in the Q2 2026. On a quarterly growth basis, Travere Therapeutics, Inc. Common Stock has generated 6.21% jump in its net profits since last 3-months.
Travere Therapeutics, Inc. Common Stock’s net profit margin fell -84.11% since last year same period to -20.52% in the Q2 2026. On a quarterly growth basis, Travere Therapeutics, Inc. Common Stock has generated 29.65% jump in its net profit margins since last 3-months.
Earnings per share (EPS) Estimates
EPS Estimate Current Quarter | 0.05 |
EPS Estimate Current Year | 0.05 |
Travere Therapeutics, Inc. Common Stock’s earning per share (EPS) estimates for the current quarter stand at 0.05 - a 135.71% jump from last quarter’s estimates.
Travere Therapeutics, Inc. Common Stock’s earning per share (EPS) estimates for the current year stand at 0.05.
Key Ratios
Earning Per Share (EPS) | -0.37 |
Travere Therapeutics, Inc. Common Stock’s earning per share (EPS) fell -384.62% since last year same period to -0.37 in the Q2 2026. This indicates that the Travere Therapeutics, Inc. Common Stock has generated -384.62% annual rate of fall in its earning per share (EPS) in the last 4 quarters.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2026-08-04 | -0.14 | -0.37 | -164.29% |
2026-05-04 | -0.06 | 0.05 | 183.33% |
